Professor Mary Ann Lumsden, BSc Hons, MB.BS, MRCOG, MD, FRCOG
Mary Ann Lumsden is Professor of Medical Education and Gynaecology, Head of the Academic Unit of Reproductive & Maternal Medicine Medicine at the University of Glasgow. She is an Honorary Consultant Obstetrician and Gynaecologist, NHS Greater Glasgow and Clyde.
Reproductive & Maternal Medicine
2nd Floor, New Lister Building
Glasgow Royal Infirmary
10-16 Alexandra Parade
Glasgow G31 2ER
tel: 0141 201 8616 (Admin 0141 201 8581)
Mary Ann graduated from Medicine from St Mary’s Hospital Medical School, University of London in 1977. Her MD was awarded in 1985.
Mary Ann’s past appointments at the University of Glasgow include Senior Lecturer and Reader before being awarded a personal chair.
Prof Lumsden is Chair of the Organising committee of the Masters Programme and Professional Doctorate in Health Professions Education with involvement in teaching and supervision of the Masters projects.
Evidence Based Medicine: Secondment to fulfil the role of Clinical Co-Director of the National Collaborating centre for Women’s and Children’s Health, funded by the National Institute of Care excellence (NICE). This centre is funded by NICE to produce guidelines in Women’s and children’s health. This has led to experience and expertise in evidence based medicine.
Other Posts held:
President Elect and Treasurer of the International Menopause Society 2014-2016
Council of the Royal College of Obstetrics and Gynaecology, Fellow’s representative for Scotland 2014-2016
Vice Chair of the Women’s Health Expert Advisory Group to the Medicine and Hormones Regulatory Authority. 2012-current, member since 2004
Chair, Guidelines Development Group for the NICE Guideline on the Investigation and Management of the Menopause, due to publish Autumn 2015.
Current Research Interests
Ongoing studies of menstrual disorders in women with uterine fibroids. Projects involve investigating factors that might be involved in the aetiology of heavy menstrual bleeding, a common problem in these women, as well as the treatment of this condition.
Currently 2 fertility sparing treatments (myomectomy and uterine artery embolisation) are being compared including impact on symptoms and Quality of Life (The FEMME Trial). Recruitment will be completed in October 2014 and the results will start to be published in 2016
McPherson K. (PI), Lumsden M.A. (CoPI), Manyonda I.T., Moss J.G., Belli A., Daniels J., Wu, O., McVeigh JE. A prospective randomised trial of myomectomy versus uterine artery embolisation (UAE) for women requiring treatment for uterine fibroids wishing to retain or improve their fertility. FEMME : Fibroids, Embolisation or MyoMectomy, Effect differences.
Lead Applicant Prof H Critchley (University of Edinburgh). This project is a collaboration between the Universities of Edinburgh, Birmingham, Glasgow and Aberdeen. Recruitment will start in October 2014. Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
The influence of ethnicity on metabolism in women in mid-life
Ongoing studies of fat distribution and metabolic parameters in South Asian women in midlife and the impact of the menopause transition.
The Mechanism of Hot Flushing
Hot flushing is the commonest symptom experienced by menopausal women and can have a significant impact on quality of life. Many women are now reluctant to take HRT and alternatives are being developed. However, it is important to understand better, the mechanism of hot flushing and also to have good biomarkers for the assessment of potential new treatments. We have used Laser Doppler Iontophoresis as a biomarker for hot flushing in healthy postmenopausal women and have conducted further studies to investigate potential treatments in healthy postmenopausal women. We are currently aiming to develop projects investigating the mechanism and treatment of hot flushing in those with breast cancer.
FEMME Trial National Institute for Health Research Health Technology Assessment Programme (£2,377,719). June 2011 for 5 years
UCON Trial Funded by MRC/ EME. (£2,022,000)
Long Term (3-5 years) follow up and MRI imaging of the REST cohort trial. Chief Scientists Office. January 2007 for 2 Years 9 months.
A study to investigate the value of Laser Doppler Iontophoresis as a biomarker for Vasomotor symptoms, TMRI Ltd. April 07 for 1 year.
Collection of Blood, Urine and Tissue Biopsy to Identify Potential Soluble Biomarkers of Endometriosis. Pfizer Global Research & Development. May 06 for 18 months.
The Working in Health Access Network, Scottish Funding Council, 1st July 2007 for 3 years.